This protocol is judged by an institutional overview board, an independent group that assessments any clinical trials involving human beings. If a analyze includes a Program I drug, as soon as the board approves the protocol as moral, the researchers have to make an application for an investigational new drug (IND) variety from the FDA.Correction: